View : 540 Download: 0
New antimicrobial bioactivity against multidrugresistant gram-positive bacteria of kinase inhibitor imd0354
- Title
- New antimicrobial bioactivity against multidrugresistant gram-positive bacteria of kinase inhibitor imd0354
- Authors
- Escobar I.E.; White A.; Kim W.; Mylonakis E.
- Ewha Authors
- 김우성
- SCOPUS Author ID
- 김우성
- Issue Date
- 2020
- Journal Title
- Antibiotics
- ISSN
- 2079-6382
- Citation
- Antibiotics vol. 9, no. 10, pp. 1 - 17
- Keywords
- High-throughput screening; IMD0354; Vancomycin-resistant Staphylococcus aureus; Vancomycinresistant enterococci
- Publisher
- MDPI AG
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Multidrug-resistant pathogens pose a serious threat to human health. For decades, the antibiotic vancomycin has been a potent option when treating Gram-positive multidrug-resistant infections. Nonetheless, in recent decades, we have begun to see an increase in vancomycin-resistant bacteria. Here, we show that the nuclear factor-kappa B (NF-κB) inhibitor N-[3,5Bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (IMD0354) was identified as a positive hit through a Caenorhabditis elegans–methicillin-resistant Staphylococcus aureus (MRSA) infection screen. IMD0354 was a potent bacteriostatic drug capable of working at a minimal inhibitory concentration (MIC) as low as 0.06 µg/mL against various vancomycin-resistant strains. Interestingly, IMD0354 showed no hemolytic activity at concentrations as high as 16 µg/mL and is minimally toxic to C. elegans in vivo with 90% survival up to 64 µg/mL. In addition, we demonstrated that IMD0354′s mechanism of action at high concentrations is membrane permeabilization. Lastly, we found that IMD0354 is able to inhibit vancomycin-resistant Staphylococcus aureus (VRSA) initial cell attachment and biofilm formation at sub-MIC levels and above. Our work highlights that the NF-κB inhibitor IMD0354 has promising potential as a lead compound and an antimicrobial therapeutic candidate capable of combating multidrug-resistant bacteria. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
- DOI
- 10.3390/antibiotics9100665
- Appears in Collections:
- 약학대학 > 약학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML